tldrdailynews.com logo

Amgen Shares Plunge on Concerns Over Obesity Drug's Bone Density Impact

1 min read
Source: Seeking Alpha
Amgen Shares Plunge on Concerns Over Obesity Drug's Bone Density Impact
Photo: Seeking Alpha
TL;DR

Amgen's shares declined after Cantor Fitzgerald raised safety concerns about its obesity drug candidate, MariTide (AMG-133), citing potential risks of bone mineral density loss.

Topics:businesshealthcare#amgen#bone-mineral-density#cantor-fitzgerald#healthcare#obesity#safety-concerns
Share this article
  1. Amgen stock slips amid obesity drug risk (update) (AMGN:NASDAQ)  Seeking Alpha
  2. Amgen stock falls as analysts mull over weight loss drug’s bone density data  CNBC
  3. A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value  STAT
  4. Amgen MariTide bone mineral density loss data ‘leaked,’ says Cantor Fitzgerald  TipRanks
  5. Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot  Investor's Business Daily

Want the full story? Read the original reporting

Read on Seeking Alpha